Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis

IMPORTANCE: Tumor necrosis factor inhibitors (TNFis) have revolutionized the management of ankylosing spondylitis (AS); however, the lack of notable clinical responses in approximately one-half of patients suggests important heterogeneity in treatment response. Identifying patients likely to respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Runsheng, Dasgupta, Abhijit, Ward, Michael M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924712/
https://www.ncbi.nlm.nih.gov/pubmed/35289857
http://dx.doi.org/10.1001/jamanetworkopen.2022.2312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924712/
https://www.ncbi.nlm.nih.gov/pubmed/35289857
http://dx.doi.org/10.1001/jamanetworkopen.2022.2312

Ejemplares similares